Senza5 CART5

BIOLOGICAL2 trials

Sponsors

Vittoria Biotherapeutics

Conditions

Participants Treated With Senza5T Cell Non-Hodgkin Lymphoma

Phase 1

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

RecruitingNCT06420089

Vittoria BiotherapeuticsT Cell Non-Hodgkin Lymphoma

Start: 2024-10-04End: 2029-08-30Target: 30Updated: 2025-11-07

Unknown Phase

A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials

Not yet recruitingNCT07683897

Vittoria BiotherapeuticsParticipants Treated With Senza5

Start: 2026-07-01End: 2041-07-01Target: 30Updated: 2026-07-30

Related Papers

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

Blood2025-11-03

CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089).

Journal of Clinical Oncology2025-05-28

Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies

Blood2024-11-051 citations

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood2024-11-051 citations